XTX Topco Ltd Takes $440,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

XTX Topco Ltd bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,972 shares of the company's stock, valued at approximately $440,000.

Several other large investors have also modified their holdings of the business. Barclays PLC grew its stake in Viridian Therapeutics by 113.1% in the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after purchasing an additional 66,550 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Viridian Therapeutics by 5.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company's stock worth $33,979,000 after buying an additional 81,951 shares in the last quarter. Exome Asset Management LLC purchased a new position in shares of Viridian Therapeutics during the third quarter valued at $3,968,000. Lord Abbett & CO. LLC bought a new stake in shares of Viridian Therapeutics in the third quarter valued at about $8,917,000. Finally, Principal Financial Group Inc. lifted its stake in Viridian Therapeutics by 1,603.4% in the third quarter. Principal Financial Group Inc. now owns 172,810 shares of the company's stock worth $3,931,000 after acquiring an additional 162,665 shares during the period.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several recent research reports. Needham & Company LLC restated a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN traded down $0.06 during midday trading on Friday, reaching $13.50. 524,676 shares of the company's stock traded hands, compared to its average volume of 1,203,124. The company has a fifty day simple moving average of $14.24 and a two-hundred day simple moving average of $18.21. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The company has a market cap of $1.10 billion, a P/E ratio of -3.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.